AP NEWS
Press release content from Business Wire. The AP news staff was not involved in its creation.
PRESS RELEASE: Paid content from Business Wire
Press release content from Business Wire. The AP news staff was not involved in its creation.

LEO Pharma and Research Project BIOMAP: Towards Personalised Medicine for Inflammatory Skin Diseases

April 11, 2019

BALLERUP, Denmark--(BUSINESS WIRE)--Apr 11, 2019--LEO Pharma, a global leader in medical dermatology and BIOMAP, a EU-funded research project (Biomarkers in Atopic Dermatitis and Psoriasis), today announced that BIOMAP kicks off its activities with the aim of improving the lives of patients affected by the two most common inflammatory skin conditions. Addressing key unmet needs in treating atopic dermatitis and psoriasis by analysing data from more than

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20190411005409/en/

50,000 patients, the five-year project will have a broad impact on disease understanding, patient care and future therapies. In addition to LEO Pharma the team comprises 26 academic and five industry partners as well as five patient organisations. The European Innovative Medicines Initiative (IMI) and the participating pharma companies provide EUR 20.8 million funding for the first IMI project in the field of dermatology.

Atopic dermatitis and psoriasis affect more than 300 million people worldwide and are highly variable in terms of onset, severity, progression over time and response to treatment. Resulting in significant morbidity and an increased risk for associated conditions such as arthritis and asthma, inflammatory skin diseases are a huge burden to patients and families, care-givers and healthcare systems. Yet, despite many years of research, there are still significant gaps in the understanding of both conditions.

The renowned clinicians and scientists of BIOMAP, who have now joined forces in a large public-private partnership, will examine the causes and mechanisms of these conditions. By analysing the largest collection of patient data ever and performing advanced molecular investigations at the single cell level and in the tissue context, they aim at identifying biomarkers for variations in disease outcome. Taking advantage of recent technical developments in translational medicine, the project will drive drug discovery and improve direct disease management by combining clinical, genetic and epidemiological expertise with modern molecular analysis techniques and newly-developed tools in bioinformatics. BIOMAP is the first IMI project in the field of dermatology.

View source version on businesswire.com:https://www.businesswire.com/news/home/20190411005409/en/

CONTACT: EURICE – European Research and Project Office GmbH

Dr Verena Peuser

Phone +49 30 374415832

Emailv.peuser@eurice.euLEO Pharma A/S

Trine Juul Wengel

Tel.: +45 20732037

Email:tewdk@leo-pharma.com

KEYWORD: EUROPE ASIA PACIFIC NORTH AMERICA CENTRAL AMERICA SOUTH AMERICA CANADA DENMARK

INDUSTRY KEYWORD: HEALTH BIOTECHNOLOGY CLINICAL TRIALS PHARMACEUTICAL RESEARCH SCIENCE

SOURCE: LEO Pharma

Copyright Business Wire 2019.

PUB: 04/11/2019 07:51 AM/DISC: 04/11/2019 07:51 AM

http://www.businesswire.com/news/home/20190411005409/en

All contents © copyright 2019 The Associated Press. All rights reserved.